Opendata, web and dolomites


Utilizing an innovative chemical platform to defeat antimicrobial resistance

Total Cost €


EC-Contrib. €






Project "QTB4AMR" data sheet

The following table provides information about the project.


Organization address
address: TVISTEVAGEN 48C
city: UMEA
postcode: 907 36
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    QURETECH BIO AB SE (UMEA) coordinator 50˙000.00


 Project objective

We tackle the challenges posed by the emergence of antimicrobial resistance (AMR) with a conceptually new approach. We have established a scalable chemical platform for the development of novel antibiotic resistance breakers (ARBs). Our compounds sensitize the pathogen and restore the effectiveness of standard-of-care antibiotics. By circumventing the painstaking process of discovering and developing new antibiotics, we bring forth a more cost-effective approach to confront the emergence of AMR. Allowing pharmaceutical companies to protect decades worth of R&D efforts and billions of euros in development costs, we present them with an attractive value proposition. Our platform enables the fast, high-yield production of ARBs against gram-positive bacteria (GmPcides). Our compounds have displayed effectiveness against two of the most threatening drug-resistant pathogens MRSA and VRE. Moreover, the compounds exhibit a strong in vivo synergy with two of the world’s most essential antibiotics Gentamicin and Vancomycin.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "QTB4AMR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "QTB4AMR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Presque (2019)

Smart Nursing Bra

Read More